Latest News from ASCO in Action

Latest News from ASCO in Action

April 24, 2014

On April 23, 2014, the U. S. Food and Drug Administration approved siltuximab (SylvantTM  Injection Janssen Biotech, Inc.), for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV-) -negative and human herpes virus -8 (HHV-8) -negative.

April 21, 2014

On April 21, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza™, Eli Lilly and Company) for use as a single agent for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.

April 17, 2014

On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra® Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.